LT3569222T - Sausų miltelių vaisto forma, apimanti anticholinerginį vaistą, kortikosteroidą ir beta adrenerginį vaistą, skirta vartoti inhaliacijos būdu - Google Patents

Sausų miltelių vaisto forma, apimanti anticholinerginį vaistą, kortikosteroidą ir beta adrenerginį vaistą, skirta vartoti inhaliacijos būdu

Info

Publication number: LT3569222T
Authority: LT; Lithuania
Prior art keywords: anticholinergic; corticosteroid; adrenergic; inhalation; beta
Prior art date: 2013-07-11

Application number

LTEP19182016.6T

Other languages

English (en)

Inventor

Irene PASQUALI

Rossella Musa

Francesca Schiaretti

Azita ASKEY-SARVAR

Original Assignee

Chiesi Farmaceutici S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-11

Filing date

2014-07-10

Publication date

2024-09-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51292914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3569222(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-07-10 Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.

2024-09-25 Publication of LT3569222T publication Critical patent/LT3569222T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Anesthesiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LTEP19182016.6T 2013-07-11 2014-07-10 Sausų miltelių vaisto forma, apimanti anticholinerginį vaistą, kortikosteroidą ir beta adrenerginį vaistą, skirta vartoti inhaliacijos būdu LT3569222T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP13176114		2013-07-11
EP13194763		2013-11-28

Publications (1)

Publication Number	Publication Date
LT3569222T true LT3569222T (lt)	2024-09-25

Family

ID=51292914

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
LTEP14747855.6T LT3019153T (lt)	2013-07-11	2014-07-10	Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta-adrenerginį agentą, skirta įvedimui inhaliacijos pagalba
LTEP18178893.6T LT3409270T (lt)	2013-07-11	2014-07-10	Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta adrenerginį agentą, skirta vartoti įkvepiant
LTEP19182016.6T LT3569222T (lt)	2013-07-11	2014-07-10	Sausų miltelių vaisto forma, apimanti anticholinerginį vaistą, kortikosteroidą ir beta adrenerginį vaistą, skirta vartoti inhaliacijos būdu

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
LTEP14747855.6T LT3019153T (lt)	2013-07-11	2014-07-10	Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta-adrenerginį agentą, skirta įvedimui inhaliacijos pagalba
LTEP18178893.6T LT3409270T (lt)	2013-07-11	2014-07-10	Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta adrenerginį agentą, skirta vartoti įkvepiant

Country Status (35)

Country	Link
US (2)	US9402825B2 (lt)
EP (3)	EP3409270B1 (lt)
JP (1)	JP6426167B2 (lt)
KR (2)	KR102275904B1 (lt)
CN (1)	CN105338960B (lt)
AR (1)	AR129501A2 (lt)
AU (1)	AU2014289185B2 (lt)
BR (1)	BR112015030914B1 (lt)
CA (1)	CA2917752C (lt)
CL (1)	CL2016000028A1 (lt)
CY (2)	CY1120806T1 (lt)
DK (3)	DK3409270T3 (lt)
EA (1)	EA029125B1 (lt)
ES (3)	ES2867552T3 (lt)
FI (1)	FI3569222T3 (lt)
GE (1)	GEP20186853B (lt)
HR (3)	HRP20182008T1 (lt)
HU (3)	HUE068270T2 (lt)
IL (1)	IL243507A0 (lt)
LT (3)	LT3019153T (lt)
MX (1)	MX2016000290A (lt)
MY (1)	MY176176A (lt)
NZ (1)	NZ715797A (lt)
PE (2)	PE20212110A1 (lt)
PH (1)	PH12016500043B1 (lt)
PL (3)	PL3569222T3 (lt)
PT (1)	PT3019153T (lt)
RS (3)	RS61652B1 (lt)
SA (1)	SA516370373B1 (lt)
SG (1)	SG11201600110RA (lt)
SI (3)	SI3409270T1 (lt)
TN (1)	TN2016000007A1 (lt)
TW (1)	TWI642450B (lt)
UA (1)	UA116907C2 (lt)
WO (1)	WO2015004243A1 (lt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ600790A (en) *	2009-12-23	2014-09-26	Chiesi Farma Spa	Combination therapy for copd
UA115543C2 (uk) *	2012-01-25	2017-11-27	К'Єзі Фармачеутічі С.П.А.	Композиція у вигляді сухого порошку, яка містить кортикостероїд та бета-адренергічний препарат, для інгаляції
BR112015030914B1 (pt) *	2013-07-11	2023-04-04	Chiesi Farmaceutici S.P.A	Formulação de pó seco
GB201321717D0 (en) *	2013-12-09	2014-01-22	Pharmachemie Bv	Inhalable Medicaments
US9554992B2 (en)	2014-06-09	2017-01-31	Chiesi Farmaceutici S.P.A.	Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
TR201407010A2 (tr)	2014-06-16	2015-12-21	Arven Ilac Sanayi Ve Ticaret Anonim Sirketi	Vilanterol formülasyonları.
JP6600961B2 (ja) *	2015-03-30	2019-11-06	ブラザー工業株式会社	表示制御装置、表示制御方法及び記憶媒体
EP3288541B1 (en) *	2015-05-01	2020-09-02	Board of Regents, The University of Texas System	Multidrug brittle matrix compositions
MA50488B1 (fr) *	2015-11-16	2021-09-30	Chiesi Farm Spa	Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
ES2890409T3 (es)	2015-11-16	2022-01-19	Chiesi Farm Spa	Un procedimiento para la preparación de una formulación de polvo seco que comprende un anticolinérgico, un corticoesteroide y un beta-adrenérgico
CA3181327A1 (en) *	2016-11-10	2018-05-17	Medisca Pharmaceutique Inc.	Pharmaceutical compounding methods and systems
KR20240104225A (ko) *	2017-05-11	2024-07-04	키에시 파르마슈티시 엣스. 피. 에이.	항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
BR112019023386A2 (pt) *	2017-05-11	2020-06-16	Chiesi Farmaceutici S.P.A.	Processo para preparar uma formulação em pó para inalação para uso em um inalador de pó seco
CN109200034A (zh) *	2017-06-30	2019-01-15	正大天晴药业集团股份有限公司	一种可吸入干粉形式的组合物及其制备方法
WO2019060595A1 (en)	2017-09-20	2019-03-28	Teva Branded Pharmaceutical Products R&D, Inc.	INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US20220331244A1 (en) *	2019-09-24	2022-10-20	Chiesi Farmaceutici S.P.A.	Novel carrier particles for dry powder formulations for inhalation
US12029709B2 (en) *	2022-08-11	2024-07-09	De Motu Cordis Pty Ltd	Inhalable epinephrine formulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070212422A1 (en)	1999-11-10	2007-09-13	Manfred Keller	Dry powder for inhalation
PT1283036E (pt)	1998-11-13	2008-03-06	Jagotec Ag	Inalador de pó seco de dose múltipla com um reservatório de pó
PE20011227A1 (es)	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en)	2000-06-21	2000-08-09	Glaxo Group Ltd	Medicament dispenser
DE60131399T3 (de) *	2000-06-27	2019-11-14	Vectura Ltd.	Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung
DK1337240T4 (en) *	2000-11-30	2015-01-05	Vectura Ltd	A process for the preparation of particles for use in a pharmaceutical composition
ES2359576T5 (es)	2002-07-31	2020-03-03	Chiesi Farm Spa	Inhalador de polvo
JO3102B1 (ar) *	2004-03-17	2017-09-20	Chiesi Framaceutici S P A	صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0425758D0 (en) *	2004-11-23	2004-12-22	Vectura Ltd	Preparation of pharmaceutical compositions
GB0613161D0 (en)	2006-06-30	2006-08-09	Novartis Ag	Organic Compounds
EP1944018A1 (en) *	2007-01-10	2008-07-16	CHIESI FARMACEUTICI S.p.A.	Micronised particles of low-dosage strength active agents for powder formulations for inhalation
NZ600790A (en) *	2009-12-23	2014-09-26	Chiesi Farma Spa	Combination therapy for copd
ES2468835T3 (es)	2009-12-23	2014-06-17	Chiesi Farmaceutici S.P.A.	Terapia combinada para EPOC
TR201000681A2 (tr)	2010-01-29	2011-08-22	B�Lg�� Mahmut	İnhalasyon yoluyla alınan kuru toz formülasyonları.
WO2011120779A1 (en) *	2010-04-01	2011-10-06	Chiesi Farmaceutici S.P.A.	Process for preparing carrier particles for dry powders for inhalation
JP5913289B2 (ja)	2010-04-21	2016-04-27	シエシーファルマセウティチィソシエタペルアチオニ	帯電を低減した粒子を提供する方法
MA34326B1 (fr) *	2010-06-22	2013-06-01	Chiesi Farma Spa	Formulation de poudre sèche comprenant un médicament antimuscarinique
UA115543C2 (uk)	2012-01-25	2017-11-27	К'Єзі Фармачеутічі С.П.А.	Композиція у вигляді сухого порошку, яка містить кортикостероїд та бета-адренергічний препарат, для інгаляції
US9393202B2 (en)	2013-04-26	2016-07-19	Chiesi Farmaceutici S.P.A	Particle size reduction of an antimuscarinic compound
BR112015030914B1 (pt) *	2013-07-11	2023-04-04	Chiesi Farmaceutici S.P.A	Formulação de pó seco

2014
- 2014-07-10 BR BR112015030914-3A patent/BR112015030914B1/pt active IP Right Grant
- 2014-07-10 RS RS20210320A patent/RS61652B1/sr unknown
- 2014-07-10 HU HUE19182016A patent/HUE068270T2/hu unknown
- 2014-07-10 TN TN2016000007A patent/TN2016000007A1/en unknown
- 2014-07-10 PL PL19182016.6T patent/PL3569222T3/pl unknown
- 2014-07-10 PE PE2021000280A patent/PE20212110A1/es unknown
- 2014-07-10 NZ NZ715797A patent/NZ715797A/en unknown
- 2014-07-10 SG SG11201600110RA patent/SG11201600110RA/en unknown
- 2014-07-10 LT LTEP14747855.6T patent/LT3019153T/lt unknown
- 2014-07-10 CA CA2917752A patent/CA2917752C/en active Active
- 2014-07-10 ES ES18178893T patent/ES2867552T3/es active Active
- 2014-07-10 TW TW103123763A patent/TWI642450B/zh active
- 2014-07-10 HU HUE18178893A patent/HUE053957T2/hu unknown
- 2014-07-10 SI SI201431806T patent/SI3409270T1/sl unknown
- 2014-07-10 HR HRP20182008TT patent/HRP20182008T1/hr unknown
- 2014-07-10 MY MYPI2016000023A patent/MY176176A/en unknown
- 2014-07-10 EP EP18178893.6A patent/EP3409270B1/en active Active
- 2014-07-10 EA EA201690006A patent/EA029125B1/ru unknown
- 2014-07-10 PL PL18178893T patent/PL3409270T3/pl unknown
- 2014-07-10 RS RS20241002A patent/RS65951B1/sr unknown
- 2014-07-10 SI SI201430976T patent/SI3019153T1/sl unknown
- 2014-07-10 LT LTEP18178893.6T patent/LT3409270T/lt unknown
- 2014-07-10 CN CN201480037266.1A patent/CN105338960B/zh active Active
- 2014-07-10 LT LTEP19182016.6T patent/LT3569222T/lt unknown
- 2014-07-10 KR KR1020217018070A patent/KR102275904B1/ko active Active
- 2014-07-10 KR KR1020167000719A patent/KR20160029797A/ko not_active Ceased
- 2014-07-10 ES ES19182016T patent/ES2986128T3/es active Active
- 2014-07-10 MX MX2016000290A patent/MX2016000290A/es active IP Right Grant
- 2014-07-10 UA UAA201600204A patent/UA116907C2/uk unknown
- 2014-07-10 DK DK18178893.6T patent/DK3409270T3/da active
- 2014-07-10 EP EP14747855.6A patent/EP3019153B1/en active Active
- 2014-07-10 PL PL14747855T patent/PL3019153T3/pl unknown
- 2014-07-10 US US14/327,920 patent/US9402825B2/en active Active
- 2014-07-10 FI FIEP19182016.6T patent/FI3569222T3/fi active
- 2014-07-10 PE PE2016000025A patent/PE20160372A1/es unknown
- 2014-07-10 AU AU2014289185A patent/AU2014289185B2/en active Active
- 2014-07-10 HR HRP20241300TT patent/HRP20241300T1/hr unknown
- 2014-07-10 WO PCT/EP2014/064824 patent/WO2015004243A1/en active Application Filing
- 2014-07-10 DK DK14747855.6T patent/DK3019153T3/en active
- 2014-07-10 PT PT14747855T patent/PT3019153T/pt unknown
- 2014-07-10 GE GEAP201414032A patent/GEP20186853B/en unknown
- 2014-07-10 HU HUE14747855A patent/HUE039827T2/hu unknown
- 2014-07-10 JP JP2016524826A patent/JP6426167B2/ja active Active
- 2014-07-10 ES ES14747855T patent/ES2699986T3/es active Active
- 2014-07-10 EP EP19182016.6A patent/EP3569222B1/en active Active
- 2014-07-10 SI SI201432094T patent/SI3569222T1/sl unknown
- 2014-07-10 RS RS20181254A patent/RS57799B1/sr unknown
- 2014-07-10 DK DK19182016.6T patent/DK3569222T3/da active
2016
- 2016-01-07 IL IL243507A patent/IL243507A0/en active IP Right Grant
- 2016-01-07 SA SA516370373A patent/SA516370373B1/ar unknown
- 2016-01-07 PH PH12016500043A patent/PH12016500043B1/en unknown
- 2016-01-08 CL CL2016000028A patent/CL2016000028A1/es unknown
- 2016-05-20 US US15/160,593 patent/US9808422B2/en active Active
2018
- 2018-11-01 CY CY181101132T patent/CY1120806T1/el unknown
2021
- 2021-03-12 CY CY20211100219T patent/CY1123937T1/el unknown
- 2021-05-06 HR HRP20210704TT patent/HRP20210704T1/hr unknown
2023
- 2023-06-01 AR ARP230101391A patent/AR129501A2/es unknown

Also Published As

Publication number	Publication date
HK1218712A1 (zh)	2017-03-10
MX2016000290A (es)	2016-04-13
EA201690006A1 (ru)	2016-07-29
LT3409270T (lt)	2021-07-26
KR102275904B1 (ko)	2021-07-13
ES2986128T3 (es)	2024-11-08
WO2015004243A1 (en)	2015-01-15
SI3019153T1 (sl)	2018-12-31
PT3019153T (pt)	2018-12-04
US20160263027A1 (en)	2016-09-15
CN105338960A (zh)	2016-02-17
AU2014289185B2 (en)	2019-05-23
IL243507A0 (en)	2016-02-29
MY176176A (en)	2020-07-24
HUE039827T2 (hu)	2019-02-28
RS65951B1 (sr)	2024-10-31
CY1123937T1 (el)	2022-05-27
EP3569222A1 (en)	2019-11-20
DK3409270T3 (da)	2021-04-26
SI3409270T1 (sl)	2021-07-30
KR20210075217A (ko)	2021-06-22
HUE068270T2 (hu)	2024-12-28
DK3019153T3 (en)	2018-11-19
LT3019153T (lt)	2018-11-26
EP3409270A1 (en)	2018-12-05
RS57799B1 (sr)	2018-12-31
DK3569222T3 (da)	2024-08-19
TW201536352A (zh)	2015-10-01
PL3569222T3 (pl)	2024-10-28
PE20160372A1 (es)	2016-05-19
AR129501A2 (es)	2024-09-04
FI3569222T3 (fi)	2024-09-24
PH12016500043B1 (en)	2018-11-23
EP3409270B1 (en)	2021-02-24
CA2917752A1 (en)	2015-01-15
CN105338960B (zh)	2019-06-04
CL2016000028A1 (es)	2016-08-05
EP3569222B1 (en)	2024-06-26
EP3019153B1 (en)	2018-09-05
TWI642450B (zh)	2018-12-01
HRP20182008T1 (hr)	2019-01-25
PH12016500043A1 (en)	2016-03-28
CA2917752C (en)	2022-05-03
HRP20241300T1 (hr)	2024-12-06
ES2867552T3 (es)	2021-10-20
ES2699986T3 (es)	2019-02-13
PL3409270T3 (pl)	2021-08-09
US9402825B2 (en)	2016-08-02
HUE053957T2 (hu)	2021-08-30
CY1120806T1 (el)	2019-12-11
US9808422B2 (en)	2017-11-07
SI3569222T1 (sl)	2024-10-30
BR112015030914A2 (lt)	2017-07-25
PL3019153T3 (pl)	2019-02-28
AU2014289185A1 (en)	2016-02-04
EA029125B1 (ru)	2018-02-28
HRP20210704T1 (hr)	2021-06-11
SG11201600110RA (en)	2016-02-26
JP2016523950A (ja)	2016-08-12
JP6426167B2 (ja)	2018-11-21
UA116907C2 (uk)	2018-05-25
EP3019153A1 (en)	2016-05-18
TN2016000007A1 (en)	2017-07-05
BR112015030914B1 (pt)	2023-04-04
RS61652B1 (sr)	2021-04-29
GEP20186853B (en)	2018-05-25
SA516370373B1 (ar)	2017-10-11
KR20160029797A (ko)	2016-03-15
US20150017248A1 (en)	2015-01-15
PE20212110A1 (es)	2021-11-04
NZ715797A (en)	2020-06-26

Publication	Publication Date	Title
IL243507A0 (en)	2016-02-29	A dry powder formulation containing an anticholinergic agent, a steroid and an adrenergic agent for inhalation administration
IL233784A0 (en)	2014-09-30	A dry powder formulation containing a corticosteroid and a beta-adrenergic agent for administration by inhalation
PT3569222T (pt)	2024-08-21	Formulação em pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação